Nkarta (NKTX) Capital Expenditures (2019 - 2026)
Nkarta's quarterly Capital Expenditures came in at $413000.0 in Q1 2026, down 20.27% year-on-year from $518000.0 in Q1 2025, and down 26.25% quarter-over-quarter from $560000.0 in Q4 2025.
Nkarta has reported Capital Expenditures for 8 years, with the latest figure at $413000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 20.27% year-over-year to $413000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 76.79% YoY), and the FY2025 full-year result was $1.2 million, down 72.6% from the prior year.
- Capital Expenditures for Q1 2026 stood at $413000.0, down from $560000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $35.0 million in Q4 2022, with the low at -$8000.0 in Q3 2025.
- Average Capital Expenditures over 5 years is $4.8 million, with a median of $1.8 million recorded in 2022.
- Year-over-year, Capital Expenditures soared 3105.67% in 2022 and sank 101.03% in 2025.
- Tracing NKTX's Capital Expenditures over 5 years: stood at $35.0 million in 2022, then plunged by 80.57% to $6.8 million in 2023, then sank by 83.8% to $1.1 million in 2024, then plunged by 49.23% to $560000.0 in 2025, then dropped by 26.25% to $413000.0 in 2026.
- The last three Capital Expenditures figures came in at $413000.0 (Q1 2026), $560000.0 (Q4 2025), and -$8000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 413,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 413,000.00 |
| Mar 31, 2026 | 413,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 777,000.00 |
| Sep 30, 2024 | 777,000.00 |
| Jun 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 6.81 Mn |
| Dec 31, 2023 | 6.81 Mn |
| Sep 30, 2023 | 6.19 Mn |
| Sep 30, 2023 | 6.19 Mn |
| Jun 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 10.33 Mn |
| Mar 31, 2023 | 4.82 Mn |
| Mar 31, 2023 | 4.82 Mn |
| Dec 31, 2022 | 35.04 Mn |
| Dec 31, 2022 | 35.04 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Sep 30, 2022 | 7.67 Mn |
| Jun 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 2.63 Mn |
| Mar 31, 2022 | 1.77 Mn |
| Mar 31, 2022 | 1.77 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 1.52 Mn |
| Sep 30, 2021 | 1.52 Mn |
| Jun 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 1.38 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 1.07 Mn |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 2.49 Mn |
| Jun 30, 2020 | 2.49 Mn |
| Mar 31, 2020 | 2.33 Mn |
| Mar 31, 2020 | 2.33 Mn |
| Dec 31, 2019 | 622,000.00 |
| Dec 31, 2019 | 622,000.00 |
| Sep 30, 2019 | 601,199.00 |
| Sep 30, 2019 | 601,199.00 |